Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4489-4491

  Bradshaw, D ^a   Malik, S ^b   Booth, C ^a   Van Houtte, M ^c   Pattery, T ^c   Waters, A ^d   Ainsworth, J ^d   Geretti, A M ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Virco BVBA   (Belgium)

^d NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS GENOME;

ADENINE; AMINO ACID SUBSTITUTION; DEOXYCYTIDINE; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LAMIVUDINE; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 36749101375     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00687-07     Document Type: Article

References (10)

1. Cherrington, J. M., A. S. Mulato, M. D. Fuller, and M. S. Chen. 1996. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl] adenine in vitro. Antimicrob. Agents Chemother. 40:2212-2216.
2. Delaugerre, C., L. Roudiere, G. Peytavin, C. Rouzioux, J. P. Viard, and M. L. Chaix. 2005. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. J. Clin. Virol. 32:241-244.
3. Hammond, J. L., U. M. Parikh, D. L. Koontz, S. Schlueter-Wirtz, C. K. Chu, H. Z. Bazmi, R. F. Schinazi, and J. W. Mellors. 2005. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2′,3′-didehydro-2′,3′-dideoxy-5- fluorocytidine. Antimicrob. Agents Chemother. 49:3930-3932.
4. Kagan, R., L. Ross, M. Winters, T. Merigan, P. Heseltine, and M. Lewinski. 2005. Adefovir-associated HIV-1 RT mutation K70E in the age of tenofovir. Antivir. Ther. 10:S103.
5. Margot, N. A., B. Lu, A. Cheng, and M. D. Miller. 2006. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med. 7:442-450.
6. Miller, M. D., P. D. Lamy, M. D. Fuller, A. S. Mulato, N. A. Margot, T. Cihlar, and J. M. Cherrington. 1998. Human immunodeficiency virus type I reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity. Mol. Pharmacol. 54:291-297.
7. Mulato, A. S., P. D. Lamy, M. D. Miller, W.-X. Li, K. E. Anton, N. S. Hellman, and J. M. Cherrington. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob. Agents Chemother. 42:1620-1628.
8. Roge, B. T., T. L. Katzenstein, N. Obel, H. Nielse, O. Kirk, and J. Gerstoft. 2002. Genotypic and phenotypic changes in antiretroviral- naïve patients experiencing failure on randomised treatment with abacavir, didanosine and stavudine. Antivir. Ther. 7:S125.
9. Ross, L., P. Gerondelis, Q. Liao, B. Wine, M. Lim, M. Shaefer, A. Rodriguez, J. Gallant, K. Limoli, W. Huang, N. Parkin, and R. Lanier. 2005. Selection of the HIV-1 reverse transcriptase mutation K70E in antiretroviral-naïve subjects treated with tenofovir/abacavir/lamivudine therapy. Antivir. Ther. 10:S102.
10. Sluis-Cremer, N., C. W. Sheen, S. Zelina, P. S. Argoti Torres, U. M. Parikh, and J. W. Mellors. 2007. Molecular mechanism by which K70E in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 51:48-53.